



# Cybin Selects Anxiety Disorder Indications for Proprietary Psychedelic Molecule CYB004

6.16.21

**TORONTO,  
CANADA**

–

June 16,  
2021

–

[Cybin](#)

Inc.

[\(NEO:CYBN\)](#)

(OTCQB:CLXPF)

“**Cybin**”



[Our Work](#)

[Investors](#)

[About Us](#)

“**Company**”),

a

biotechnology

company

focused

on

progressing

psychedelic

therapeutics,

today

announced

that

it

has

selected

social

anxiety

disorder

(“SAD”)

and

generalized

anxiety

disorder

(“GAD”)

as



Our Work

Investors

About Us

target  
indications  
for  
its  
proprietary  
psychedelic  
molecule  
CYB004.

“People  
struggle  
with  
many  
different  
mental  
health  
challenges,  
but  
anxiety  
affects  
more  
people  
than  
any  
other,”



Our Work

Investors

About Us

Alex  
Belser,  
Chief  
Clinical  
Officer.  
“With  
the  
advent  
of  
the  
COVID-  
19  
pandemic,  
rates  
of  
anxiety  
have  
increased  
3-  
fold,  
leaving  
many  
folks  
in  
a



[Our Work](#)

[Investors](#)

[About Us](#)

We think that treatment with psychedelic medicine may help. Our team's previous research on anxiety at New York University and the trials conducted at UCLA



Our Work

Investors

About Us

Hopkins  
showed  
large  
magnitude  
decreases  
in  
anxiety  
after  
treatment  
with  
psychedelic-  
assisted  
psychotherapy.

This  
is  
a  
promising  
approach  
to  
treat  
anxiety  
with  
a  
clear  
pathway.”



[Our Work](#)

[Investors](#)

[About Us](#)

called  
social  
phobia,  
describes  
the  
persistent  
and  
irrational  
fear  
of  
embarrassment  
and  
humiliation  
in  
social  
situations.  
SAD  
typically  
begins  
in  
childhood  
or  
adolescence  
and,  
untreated,



Our Work

Investors

About Us

associated  
with  
the  
subsequent  
development  
of  
major  
depression,  
substance  
abuse,  
and  
other  
mental  
health  
problems.

The  
disorder  
can  
be  
associated  
with  
extensive  
functional  
impairment  
and





[Our Work](#)

[Investors](#)

[About Us](#)

of  
life.  
SAD  
is  
a  
prevalent  
condition,  
estimated  
to  
affect  
between  
3%  
and  
7%  
of  
the  
United  
States  
adult  
population.

**SAD  
Market  
Size:  
Based**



[Our Work](#)

[Investors](#)

[About Us](#)

derived  
from  
currently  
available  
FDA  
approved  
treatments,  
the  
current  
US  
market  
is  
estimated  
at  
US\$165M  
with  
global  
estimates  
at  
US\$1.15B  
as  
of  
2021.  
The  
market



[Our Work](#)

[Investors](#)

[About Us](#)

made  
up  
of  
multiple  
approved  
drugs  
still  
under  
patent  
protection,  
generics  
and  
off  
label  
use  
drugs.

GAD  
is  
marked  
by  
excessive  
anxiety  
and  
worry



Our Work

Investors

About Us

about  
a  
range  
of  
everyday  
topics/events  
and  
is  
one  
of  
the  
most  
common  
mental  
disorders  
in  
both  
community  
and  
clinical  
settings  
and  
is  
associated  
with



[Our Work](#)

[Investors](#)

[About Us](#)

of  
health  
care  
services.

GAD  
is  
a  
prevalent  
condition,  
estimated  
to  
affect  
between  
3%  
and  
6%  
of  
the  
United  
States  
adult  
population.

**GAD**  
**Market**



[Our Work](#)

[Investors](#)

[About Us](#)

global estimates are approximately US\$2.99B and projected to grow to US\$4.5B by 2027.

The market is currently made up of multiple approved drugs still under



Our Work

Investors

About Us

generics  
and  
off  
label  
use  
drugs,  
including  
benzodiazepines  
which  
carry  
a  
risk  
of  
addiction,  
misuse  
and  
dependence.

According  
to  
The  
World  
Health  
Organization  
(WHO),



Our Work

Investors

About Us

13  
adults  
globally  
suffers  
from  
anxiety.  
Current  
FDA-  
approved  
medications  
for  
anxiety  
disorders  
include  
SSRIs  
and  
SNRIs,  
which  
have  
slow  
onset  
of  
action  
and  
side-





[Our Work](#)

[Investors](#)

[About Us](#)

weight gain, nausea, vomiting and sexual dysfunction.

Many patients also do not respond to SSRI or SNRI treatments for the anxiety disorders.

Various studies



Our Work

Investors

About Us

improvements  
in  
anxiety  
with  
psychedelic  
treatments  
showed  
a  
significant  
response  
to  
therapy  
and  
were  
relatively  
well-  
tolerated.

In  
these  
studies,  
patients  
benefited  
from  
a  
faster



Our Work

Investors

About Us

action  
with  
less  
addictive  
effects.

"The  
decision  
to  
pursue  
anxiety  
disorders  
indications  
for  
CYB004  
follows  
months  
of  
thoughtful,  
in-  
depth  
work  
by  
the  
Cybin



Our Work

Investors

About Us

Careful  
consideration  
of  
many  
factors  
drives  
these  
decisions,  
including  
the  
prevalence  
of  
anxiety  
disorders,  
the  
measurable  
clinical  
endpoints,  
a  
realistic  
pre-  
clinical  
and  
clinical  
plan,



[Our Work](#)

[Investors](#)

[About Us](#)

an  
understanding  
of  
the  
effects  
of  
the  
molecule  
itself.

For  
the  
Cybin  
team,  
this  
decision  
represents  
a  
further  
opportunity  
to  
help  
millions  
of  
sufferers  
of



[Our Work](#)

[Investors](#)

[About Us](#)

too-  
prevalent  
disorders,”  
stated  
Doug  
Drysdale,  
Chief  
Executive  
Officer.

## References

Anxiety  
&  
Depression  
Association  
of  
America.

Belser,  
A.  
B.,  
Agin-  
Liebes,  
G.,  
Swift,



Our Work

Investors

About Us

Terrana,  
S.,  
Devenot,  
N.,  
Friedman,  
H.  
L.,  
...  
&  
Ross,  
S.  
(2017).

Patient  
experiences  
of  
psilocybin-  
assisted  
psychotherapy:  
an  
interpretative  
phenomenological  
analysis.  
Journal  
of  
Humanistic



[Our Work](#)

[Investors](#)

[About Us](#)

354-  
388.  
Danforth,  
A.  
L.,  
Struble,  
C.  
M.,  
Yazar-  
Klosinski,  
B.,  
&  
Grob,  
C.  
S.  
(2016).  
MDMA-  
assisted  
therapy:  
a  
new  
treatment  
model  
for





[Our Work](#)

[Investors](#)

[About Us](#)

in  
autistic  
adults.  
Progress  
in  
Neuro-  
Psychopharmacology  
and  
Biological  
Psychiatry,  
64,  
237-  
249.  
Dos  
Santos,  
R.  
(2018).  
Efficacy,  
tolerability,  
and  
safety  
of  
serotonergic  
psychedelics



[Our Work](#)

[Investors](#)

[About Us](#)

management  
of  
mood,  
anxiety,  
and  
substance-  
use  
disorders:  
a  
systematic  
review  
of  
systematic  
reviews.  
Expert  
review  
of  
Clinical  
Pharmacology,  
Vol.  
11,  
No.  
9,  
889–  
902.



[Our Work](#)

[Investors](#)

[About Us](#)

Intelligence

Center.

(2021).

Epidemiology

Market

Size

Data.

[Data

File].

Retrieved

from

[pharma.globaldata.com](https://pharma.globaldata.com)

GlobalData

Pharma

Intelligence

Center.

(2021).

Annual

Sales

and

Forecast.

[Data

File].

Retrieved



Our Work

Investors

About Us

Griffiths,

R.

R.,

Johnson,

M.

W.,

Carducci,

M.

A.,

Umbricht,

A.,

Richards,

W.

A.,

Richards,

B.

D.,

...

&

Klinedinst,

M.

A.

(2016).

Psilocybin



[Our Work](#)

[Investors](#)

[About Us](#)

and  
sustained  
decreases  
in  
depression  
and  
anxiety  
in  
patients  
with  
life-  
threatening  
cancer:  
A  
randomized  
double-  
blind  
trial.  
Journal  
of  
psychopharmacology,  
30(12),  
1181-  
1197.



Our Work

Investors

About Us

S.,  
Danforth,  
A.  
L.,  
Chopra,  
G.  
S.,  
Hagerty,  
M.,  
McKay,  
C.  
R.,  
Halberstadt,  
A.  
L.,  
&  
Greer,  
G.  
R.  
(2011).  
Pilot  
study  
of  
psilocybin  
treatment



[Our Work](#)

[Investors](#)

[About Us](#)

in  
patients  
with  
advanced-  
stage  
cancer.

Archives  
of  
general  
psychiatry,  
68(1),  
71-  
78.

Harvard  
Medical  
School,  
2007.

National  
Comorbidity  
Survey  
(NCS).  
(2017,  
August



Our Work

Investors

About Us

Kessler,  
R.  
C.  
(2005).  
Lifetime  
Prevalence  
and  
Age-  
of-  
Onset  
Distributions  
of  
DSM-  
IV  
Disorders  
in  
the  
National  
Comorbidity  
Survey  
Replication.  
Arch  
Gen  
Psychiatry,





[Our Work](#)

[Investors](#)

[About Us](#)

602.

Kessler,

R.

C.,

Berglund,

P.,

Demler,

O.,

Jin,

R.,

Merikangas,

K.

R.,

&

Walters,

E.

E.

(2005).

Lifetime

prevalence

and

age-

of-

onset



[Our Work](#)

[Investors](#)

[About Us](#)

DSM-  
IV  
disorders  
in  
the  
National  
Comorbidity  
Survey  
Replication.  
Archives  
of  
general  
psychiatry,  
62(6),  
593-  
602.  
Muttonia,  
S.  
(2019).  
Classical  
psychedelics  
for  
the  
treatment



[Our Work](#)

[Investors](#)

[About Us](#)

and  
anxiety:  
A  
systematic  
review.  
Journal  
of  
Affective  
Disorders,  
258:11-  
24.  
Ross,  
S.,  
Bossis,  
A.,  
Guss,  
J.,  
Agin-  
Liebes,  
G.,  
Malone,  
T.,  
Cohen,  
B.,



Our Work

Investors

About Us

Belser,  
A.,  
Kalliontzi,  
K.,  
Babb,  
J.,  
Su,  
Z.,  
Corby,  
P.  
&  
Schmidt,  
B.  
L.  
(2016).  
Rapid  
and  
sustained  
symptom  
reduction  
following  
psilocybin  
treatment  
for  
anxiety

[Our Work](#)[Investors](#)[About Us](#)

in  
patients  
with  
life-  
threatening  
cancer:  
a  
randomized  
controlled  
trial.  
Journal  
of  
psychopharmacology,  
30(12),  
1165-  
1180.  
Ruscio,  
A.  
M.  
(2008).  
Psychological  
Medicine,  
38(1):15-  
28.



[Our Work](#)

[Investors](#)

[About Us](#)

Lasheras,  
I.,  
Lipnicki,  
D.  
M.,  
Bueno-  
Notivol,  
J.,  
Pérez-  
Moreno,  
M.,  
López-  
Antón,  
R.,  
...  
&  
Gracia-  
García,  
P.  
(2021).  
Prevalence  
of  
anxiety  
in  
the



Our Work

Investors

About Us

pandemic:  
An  
updated  
meta-  
analysis  
of  
community-  
based  
studies.

Progress  
in  
Neuro-  
Psychopharmacology  
and  
Biological  
Psychiatry,  
109,  
110207.

Siegel,  
A.  
N.  
(2021).

Registered  
clinical



Our Work

Investors

About Us

psychedelic  
drugs  
for  
psychiatric  
disorders.

Journal  
of  
Psychiatric  
Research,  
139:  
71-  
81.

Weston,  
N.  
M.  
(2020).

Historic  
psychedelic  
drug  
trials  
and  
the  
treatment  
of





[Our Work](#)

[Investors](#)

[About Us](#)

Depression

Anxiety,

37:1261-

1279.

## About

### Cybin

Cybin

is

a

leading

biotechnology

company

focused

on

progressing

psychedelic

therapeutics

by

utilizing

proprietary

drug

discovery

platforms,



[Our Work](#)

[Investors](#)

[About Us](#)

delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.

**Cautionary Notes and Forward-Looking Statements**

Certain statements in this news release



[Our Work](#)

[Investors](#)

[About Us](#)

the  
Company  
are  
forward-  
looking  
statements  
and  
are  
prospective  
in  
nature.

Forward-  
looking  
statements  
are  
not  
based  
on  
historical  
facts,  
but  
rather  
on  
current  
expectations



Our Work

Investors

About Us

about  
future  
events  
and  
are  
therefore  
subject  
to  
risks  
and  
uncertainties  
which  
could  
cause  
actual  
results  
to  
differ  
materially  
from  
the  
future  
results  
expressed  
or



[Our Work](#)

[Investors](#)

[About Us](#)

the  
forward-  
looking  
statements.

These  
statements  
generally

can  
be  
identified

by  
the  
use  
of

forward-  
looking  
words  
such

as  
“may”,  
“should”,  
“could”,  
“intend”,  
“estimate”,  
“plan”,



Our Work

Investors

About Us

“believe”

or

“continue”,

or

the

negative

thereof

or

similar

variations.

Forward-

looking

statements

in

this

news

release

may

include

statements

regarding

enhanced

liquidity,

the

value



Our Work

Investors

About Us

capital  
markets  
exposure,  
access  
to  
institutional  
and  
retail  
investors,  
the  
Company's  
new  
strategic  
brand  
messaging  
campaign,  
and  
psychedelic  
drug  
development  
programs  
to  
potentially  
treat  
mental



[Our Work](#)

[Investors](#)

[About Us](#)

There are numerous risks and uncertainties that could cause actual results and Cybin's plans and objectives to differ materially from those expressed in the forward-





Our Work

Investors

About Us

Actual results and future events could differ materially from those anticipated in such information.

These and all subsequent written and oral forward-looking information are



[Our Work](#)

[Investors](#)

[About Us](#)

estimates  
and  
opinions  
of  
management  
on  
the  
dates  
they  
are  
made  
and  
are  
expressly  
qualified  
in  
their  
entirety  
by  
this  
notice.  
Except  
as  
required  
by



[Our Work](#)

[Investors](#)

[About Us](#)

Company  
does  
not  
intend  
to  
update  
these  
forward-  
looking  
statements.

Cybin  
makes  
no  
medical,  
treatment  
or  
health  
benefit  
claims  
about  
Cybin's  
proposed  
products.  
The



[Our Work](#)

[Investors](#)

[About Us](#)

and  
Drug  
Administration,  
Health  
Canada  
or  
other  
similar  
regulatory  
authorities  
have  
not  
evaluated  
claims  
regarding  
psilocybin,  
psychedelic  
tryptamine,  
tryptamine  
derivatives  
or  
other  
psychedelic  
compounds  
or



[Our Work](#)

[Investors](#)

[About Us](#)

The efficacy of such products has not been confirmed by approved research.

There is no assurance that the use of psilocybin, psychedelic tryptamine, tryptamine derivatives



Our Work

Investors

About Us

psychedelic  
compounds  
or  
nutraceuticals  
can  
diagnose,  
treat,  
cure  
or  
prevent  
any  
disease  
or  
condition.  
Vigorous  
scientific  
research  
and  
clinical  
trials  
are  
needed.  
Cybin  
has  
not



Our Work

Investors

About Us

trials  
for  
the  
use  
of  
its  
proposed  
products.  
Any  
references  
to  
quality,  
consistency,  
efficacy  
and  
safety  
of  
potential  
products  
do  
not  
imply  
that  
Cybin  
verified



Our Work

Investors

About Us

clinical  
trials  
or  
that  
Cybin  
will  
complete  
such  
trials.  
If  
Cybin  
cannot  
obtain  
the  
approvals  
or  
research  
necessary  
to  
commercialize  
its  
business,  
it  
may  
have





Our Work

Investors

About Us

adverse  
effect  
on  
Cybin's  
performance  
and  
operations.

*The  
NEO  
Exchange  
has  
neither  
approved  
nor  
disapproved  
the  
contents  
of  
this  
news  
release  
and  
is*



Our Work

Investors

About Us

*for  
the  
adequacy  
and  
accuracy  
of  
the  
contents  
herein.*

**Investor**

**Contacts:**

Tim

Regan/Scott

Eckstein

KCSA

Strategic

Communications

[Cybin@kcsa.com](mailto:Cybin@kcsa.com)

Lisa

M.

Wilson



[Our Work](#)

[Investors](#)

[About Us](#)

Communications,  
Inc.

[lwilson@insitecony.com](mailto:lwilson@insitecony.com)

### Media

#### Contacts:

John

Kanakis

Cybin

Inc.

[John@cybin.com](mailto:John@cybin.com)

[PREVIOUS POST](#)

[NEXT POST](#)



Our Work

Investors

About Us



5600-100 King St W, Toronto ON  
M5X 1C9  
Investor Contact: [ir@cybin.com](mailto:ir@cybin.com)  
General Contact:  
[info@cybin.com](mailto:info@cybin.com)

Our Work

[Development Pipeline](#)

[The Science](#)

[Cybin x Kernel](#)

Investors

[Press Releases](#)

[Financials](#)

[Corporate Governance](#)

[Downloads](#)

About Us

[Mission](#)

[Team](#)

[News](#)

[Join Us](#)

[Contact](#)

Copyright © 2019 Cybin. All rights reserved.

[Privacy Policy](#)